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Abstract
Introduction Truncation mutations in the BRCA1 gene cause a
substantial increase in risk of breast cancer. However, these
mutations are rare in the general population and account for little
of the overall incidence of sporadic breast cancer.
Method We used whole-gene resequencing data to select
haplotype tagging single nucleotide polymorphisms, and
examined the association between common haplotypes of
BRCA1 and breast cancer in a nested case-control study in the
Nurses' Health Study (1323 cases and 1910 controls).
Results One haplotype was associated with a slight increase in
risk (odds ratio 1.18, 95% confidence interval 1.02–1.37). A
significant interaction (P  = 0.05) was seen between this
haplotype, positive family history of breast cancer, and breast
cancer risk. Although not statistically significant, similar
interactions were observed with age at diagnosis and with
menopausal status at diagnosis; risk tended to be higher among
younger, pre-menopausal women.
Conclusions We have described a haplotype in the BRCA1
gene that was associated with an approximately 20% increase
in risk of sporadic breast cancer in the general population.
However, the functional variant(s) responsible for the
association are unclear.
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Introduction
Truncation mutations in the BRCA1 gene are high-pene-
trance, low-prevalence factors in risk of breast cancer.
BRCA1 is hypothesized to be a locus under recombina-
tional inhibition, and very few haplotypes have been
described. In fact, only one haplotype block and two major
haplotypes have been shown to exist in Caucasians.
Because of the size of the gene (more than 80 kilobases),
polymorphism discovery screenings have focused on
exons. Although many non-synonymous polymorphisms are
known in the gene, the degree of linkage disequilibrium
(LD) across the entire region limits genetic variability. This
limited variability has led to inconclusive results in the risk
of sporadic breast cancer associated with variants in the
BRCA1 gene [1,2].
The high degree of LD at BRCA1  led Huttley and col-
leagues [3] to investigate the possibility of recent selective
pressure being exerted on this gene. They found that
whereas the ratio of non-synonymous to synonymous
nucleotide substitutions is the same between the chimpan-
zee and humans, this ratio is different from other primates,
and greater than 1. They also note that these differences
occur in the region of BRCA1 that interacts with Rad51,
suggesting that it is the role of BRCA1 in maintaining
genome integrity that has driven this selection.
Paradoxically, BRCA1 has a large number of Alu repeat
sequences. These are repetitive elements that are thought
to be involved in recombination and evolution of the
genome [4,5]. Given that knocking out brca1 in mice is
embryonic lethal [6], it can be hypothesized that the
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apparent suppression of recombination at BRCA1 in the
human is due to the non-viability of recombinants.
Recently, resequencing information over the entire region
of the gene, including most introns, has become publicly
available [7]. We used these data to select haplotype tag-
ging single nucleotide polymorphisms (htSNPs), to test the
association of these haplotypes with breast cancer risk in a
nested case-control study within the Nurses' Health Study.
Method
Resequencing information from the Environmental
Genome Project of the National Institute of Environmental
Health Sciences (NIEHS) at the University of Washington
was used to generate haplotypes for the selection of
htSNPs [7]. There were 90 individuals with 301 SNPs in
the whole data set. SNPs were excluded from analysis if
they were out of Hardy–Weinberg equilibrium (P < 0.05),
had a minor allele frequency of less than 5%, or had more
than 25% missing data. Haplotypes were reconstructed
with PHASE [8], and htSNPs were determined with BEST
[9]. Four htSNPs were selected, at positions 33,420
(rs799917, P871L), 38,085 (rs8176166), 44,059
(rs3737559), and 64,646 (rs8176267, base pairs
reported as on GenBank sequence AY273801).
These htSNPs were genotyped in cases and controls using
the TaqMan system (Applied Biosystems, Foster City, CA).
Primer and probe sequences are available from the authors
on request. Our study consisted of 1323 breast cancer
cases and 1910 controls, nested within the prospective
Nurses' Health Study. The Nurses' Health study was initi-
ated in 1976, when 121,700 United States registered
nurses between the ages of 30 and 55 years returned an
initial questionnaire reporting medical histories and base-
line health-related exposures. Updated information has
been obtained by questionnaire every 2 years. Incident
breast cancers were identified by self-report and confirmed
by medical record review. Between 1989 and 1990, blood
samples were collected from 32,826 women. Follow-up
has been about 98% in all subsequent questionnaire
cycles for this subcohort. Eligible cases in this study con-
sisted of women with incident breast cancer from the sub-
cohort who gave a blood specimen. Cases with a diagnosis
any time after blood collection up to 1 June 2000 with no
previously diagnosed cancer except for nonmelanoma skin
cancer were included. Controls were randomly selected
participants who gave a blood sample and were free of
diagnosed cancer (except nonmelanoma skin cancer), and
were matched to cases on the basis of age, menopausal
status, recent post-menopausal hormone use, and time,
day, and month of blood collection. Table 1 shows basic
characteristics of cases and controls.
Haplotype frequencies were estimated with the EM algo-
rithm, as implemented in SAS PROC Haplotype (SAS Insti-
tute, Cary, NC). Omnibus tests of haplotype association
and haplotype-specific odds ratios (ORs) were calculated
by haplotype replacement regression [10], assuming an
additive model using the probability of carrying each pair of
haplotypes provided by PROC Haplotype. The most com-
mon haplotype was used as the reference, and rare haplo-
types (combined frequency less than 0.5%) were dropped
from analysis. Unconditional logistic regression analyses
were used to determine relative risk, controlling for age,
family history of breast cancer, history of benign breast dis-
ease, post-menopausal hormone use, parity, age at first
birth, and age of menopause. We assumed an additive
model, where haplotype-specific parameters represent the
per-haplotype increase in log odds of disease. Departures
from a multiplicative gene × environment interaction model
were tested by means of likelihood ratio tests.
A fifth SNP (Q356R, rs1799950), previously described as
being associated with a reduced risk of breast cancer [1],
was also examined with a TaqMan assay. This SNP was not
present at more than 5% in the resequencing data and
therefore was not included in our haplotype analysis. All P
values reported are two sided.
Sequence alignments were performed with base pairs
64,601–64,700 on GenBank sequence AY273801. Blast
Table 1
Basic characteristics of cases and controls
Characteristic Cases (n = 1322) Controls (n = 1908)
First-degree family history of breast cancer (%) 256 (19) 242 (13)
History of benign breast disease (%) 853 (65) 972 (51)
Post-menopausal status (%) 1133 (91) 1691 (93)
Ever used post-menopausal hormone (%) 902 (76) 1195 (68)
Age at diagnosis (selection in controls, SD) 62.9 (7.4) 63.4 (7.1)
Age at menopause (SD) 48.2 (5.8) 47.8 (6.2)Available online http://breast-cancer-research.com/content/7/2/R171
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alignments were performed over the web at http://
www.ncbi.nlm.nih.gov/BLAST/ using the blastn program
against the alu_repeats database. No filtering was used,
and expected values were set at 10-20 to limit the number
of hits. All other default values were used. AluSp repeats on
contig NT_010755 were selected from the AluGene data-
base http://alugene.tau.ac.il/. These sequences were
aligned with ClustalW at http://www.ebi.ac.uk/clustalw/,
using all default values.
Results and Discussion
The polymorphism at codon 356 in the BRCA1 gene had
previously been described as being inversely associated
with breast cancer risk (Gln356→ Arg, OR 0.88, 95% con-
fidence interval [CI] 0.63–1.23; Arg356→ Arg, OR 0.00,
95% CI 0.00–0.56) [1]. We were unable to reproduce
these results in our data set. Dunning and colleagues did
not observe any homozygotes of the Arg allele at this codon
among cases (n = 765). In contrast, we observed homozy-
gotes among both cases and controls, and did not detect
any association (Table 2). We had about 80% power to
detect a relative risk of 0.73 assuming a log additive model.
This polymorphism was not detected above the 5% thresh-
old for inclusion as a htSNP in the NIEHS database, and
was not included in our haplotype analyses. We did explore
its inclusion in the haplotype analyses, and it did not mate-
rially alter the risk estimates for other haplotypes.
Five haplotypes of more than 5% frequency were
described from the 39 polymorphisms meeting the selec-
tion criteria. BRCA1 exists as one haplotype block, with
significant LD along the entire gene. Only four SNPs were
needed to tag these haplotypes. To test the hypothesis that
a difference in haplotype frequencies is seen between
cases and controls, a global test was performed (P = 0.08).
This test is not formally significant; this should be kept in
mind while interpreting results based on haplotype analy-
sis. Table 3 shows the results of the regression trend test
of haplotypes.
Haplotype 2 (C A G G) was associated with a small,
though significant, increase in risk (OR 1.18, 95% CI 1.02–
1.37; Table 3). When considering the diplotype of haplo-
type 2, a significant increase in risk was observed among
the homozygous carriers (OR 1.62, 95% CI 1.05–2.48;
Table 4). A nearly significant interaction was seen between
haplotype 2 and family history of breast cancer (P = 0.05).
A large increase in risk (OR 10.83, 95% CI 2.39–49.2)
was observed in women homozygous for haplotype 2 and
having a positive family history of breast cancer (Table 5).
Similar, although not statistically significant, interactions
were seen for age of diagnosis (less than 50 or more than
50, interaction P = 0.36) and menopausal status at diagno-
sis (pre-menopausal or post-menopausal, interaction P =
0.19, data not shown). Additional studies focusing on
Table 2
Relation of Q356R and breast cancer risk in the Nurses' Health Study
Genotype Case (frequency)a Control (frequency)a OR (95% CI) ORb (95% CI)
Q356Q 1065 (86.23) 1413 (87.01) 1.00 (reference) 1.00 (reference)
Q356R 165 (13.36) 206 (12.68) 1.06 (0.85–1.32) 1.05 (0.84–1.32)
R356R 5 (0.4) 5 (0.31) 1.33 (0.38–4.59) 1.67 (0.44–6.35)
CI, confidence interval; OR, odds ratio.
aSamples lacking genotype information were removed from analysis.
bLogistic regression controlling for age, age of menopause, post-menopausal hormone use, age at first birth, parity, family history of breast cancer, 
and history of benign breast disease.
Table 3
Relation of common BRCA1 haplotypes to risk of breast cancer in the Nurses' Health Study
Haplotypea Caseb (frequency) Controlb (frequency) OR (95% CI) ORc (95% CI)
C A G A 1195(46) 1637 (48) 1.0 (reference) 1.0 (reference)
C A G G 536 (20) 623 (18) 1.19 (1.03–1.37) 1.18 (1.02–1.37)
T A A A 233 (9) 281 (8) 1.11 (0.95–1.29) 1.13 (0.96–1.32)
T A G A 273 (10) 403 (12) 0.92 (0.77–1.10) 0.94 (0.78–1.13)
T G G A 384 (15) 475 (14) 1.15 (0.95–1.39) 1.13 (0.93–1.37)
CI, confidence interval; OR, odds ratio.
aOrder of SNPs: 33420 (rs799917, P871L), 38085 (rs8176166), 44059 (rs3737559), 64646 (rs8176267).
bSamples lacking genotype information at all four SNPs were removed from haplotype analysis.
cLogistic regression controlling for age, age of menopause, post-menopausal hormone use, age at first birth, parity, family history of breast cancer, 
and history of benign breast disease. ORs represent risk increase per copy of each haplotype carried. P for global test = 0.08.Breast Cancer Research    Vol 7 No 2    Cox et al.
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breast cancer incidence in younger, pre-menopausal
women would be of interest, to improve the definition of risk
associated with this haplotype.
Little is known about the actual effects on the expression or
function of these polymorphisms in BRCA1. Because of
the low complexity of the gene at the haplotype level, we
can describe haplotype 2 by using just one SNP, at base
pair 64,646. This is in the intron between exons 19 and 20,
in the middle of an Alu repeat sequence. This is a rather
long intron, spanning 6 kilobases (63,044–69,242). The
Alu repeat surrounding base pair 64,646 is a member of
the AluSp family. Aligning this sequence against the Alu
database at NCBI shows that the consensus nucleotide for
this family at this position is G, which is the risk allele. Align-
ment with other AluSp repeats on the same contig as
BRCA1 shows that those most similar to this region also
have a G at this position. This implies that the G allele might
recombine more readily than the A allele with other Alu
repeats in this region. It could therefore be hypothesized
that this SNP is influential in Alu-mediated non-homologous
recombination and other rearrangements of the BRCA1
gene. These sorts of aberrations are responsible for
roughly 10% of BRCA1 disease-causing mutations, and
could be involved in somatic alteration of the structure of
the BRCA1 gene [11]. However, it is important to note that
this SNP was selected not because of any prior knowledge
of potential function but because it tags a common
haplotype.
This risk haplotype is a subset of the wild-type haplotype,
and no coding or potential splice-site SNPs in the NIEHS
Environmental Genome Project database are in LD with the
SNP defining this haplotype. It should be noted that the
sequencing data reported by the NIEHS Environmental
Genome Project are limited to about 1 kilobase of
sequence 5' to the start of transcription, and although the
entire 3' untranslated region has been sequenced, only
about 800 base pairs beyond the poly(A) site are included.
Additionally, 13,403 of 82,899 base pairs (16%) of the
genomic region of BRCA1 was not sequenced. However,
all the unsequenced regions are intronic. This leaves the
possibility that a potentially functional SNP in the
unsequenced regions of the BRCA1 gene resides on hap-
lotype 2.
Osorio and colleagues [12] examined the occurrence of
mutations in BRCA1 among the index cases of familial
Table 4
Relative risk of breast cancer by haplotype 2 status in the Nurses' Health Study
Diplotype Case (frequency) Control (frequency)a OR (95% CI) ORb (95% CI)
Other/other 832 (63) 1137 (66) 1.00 (reference) 1.00 (reference)
Hap2/other 429 (33) 531 (31) 1.11 (0.95–1.30) 1.09 (0.92–1.28)
Hap2/Hap2 53 (4.0) 47 (2.7) 1.62 (1.07–2.49) 1.62 (1.05–2.48)
CI, confidence interval; Hap2, haplotype 2; OR, odds ratio.
aSamples lacking genotype information at all four SNPs were removed from haplotype analysis.
bLogistic regression controlling for age, age of menopause, post-menopausal hormone use, age at first birth, parity, family history of breast cancer, 
and history of benign breast disease. P value for trend = 0.05.
Table 5
Haplotype 2 and risk of breast cancer by family history of breast cancer in the Nurses' Health Study
Family history Case (frequency)a Control (frequency)a OR (95% CI) ORb (95% CI)
None
Other/other 668 (51) 995 (58) 1.00 (reference) 1.00 (reference)
Hap2/other 351 (27) 456 (27) 1.16 (0.97–1.38) 1.13 (0.95–1.35)
Hap2/Hap2 39 (2.9) 43(2.5) 1.36 (0.86–2.15) 1.34 (0.84–2.15)
Present
Other/other 165 (12) 145 (8) 1.69 (1.33–2.17) 1.78 (1.38–2.29)
Hap2/other 77 (5.8) 75 (4.4) 1.51 (1.07–2.12) 1.60 (1.13–2.27)
Hap2/Hap2 14 (1.1) 3 (0.2) 10.06 (2.25–45.0) 10.83 (2.39–49.2)
CI, confidence interval; Hap2, haplotype 2; OR, odds ratio.
aSamples lacking genotype information at all four SNPs were removed from haplotype analysis.
bLogistic regression controlling for age, age of menopause, post-menopausal hormone use, age at first birth, parity, and history of benign breast 
disease. P interaction = 0.05.Available online http://breast-cancer-research.com/content/7/2/R171
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breast and ovarian cancers. They found that mutations
occur more readily on the rarer of the two common haplo-
types of BRCA1 (their haplotype II). These haplotypes are
the third, fourth and fifth listed in Table 3, not the haplotype
for which we observed an increase in risk, so the relevance
of their observation for our findings is unclear.
Although we cannot rule out the possibility that these
results are spurious or due to population stratification, the
Nurses' Health Study consists almost entirely of Caucasian
women; population stratification should therefore be mini-
mal. Two additional hypotheses that need further examina-
tion are that there are functional polymorphisms in the
BRCA1 gene that are not in the coding sequence, and/or
that variants in BRCA1 are in LD with functional variants in
neighboring genes. The LD block around BRCA1 is quite
extensive [13], and includes a BRCA1 pseudogene, as
well as the genes NBR1 and NBR2. Potentially functional
variation in these genes also needs to be described.
Conclusions
We have described a haplotype associated with the
BRCA1  gene that is associated with an approximately
20% increase in risk of sporadic breast cancer in the gen-
eral population. However, the functional variant(s) respon-
sible for the association are unclear.
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